Upregulation of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in the heart and the kidney of growth hormone receptor knock-out mice

Growth Hormone and IGF Research

Volumn 22, Issue 6, 2012, Pages 224-233

  Giani, Jorge F ^a   Miquet, Johanna G ^a   Muñoz, Marina C ^a   Burghi, Valeria ^a   Toblli, Jorge E ^b   Masternak, Michal M ^d,e   Kopchick, John J ^f   Bartke, Andrzej ^c   Turyn, Daniel ^a   Dominici, Fernando P ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^e INSTITUTE OF HUMAN GENETICS   (Poland)

^f OHIO UNIVERSITY   (United States)

Author keywords

Angiotensin (1 7); AT1 receptor; Growth hormone; Mas receptor; Renin angiotensin system

Indexed keywords

ANGIOTENSIN (1-7); ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GROWTH HORMONE RECEPTOR; MAS RECEPTOR; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART DEVELOPMENT; HORMONE RESISTANCE; IMMUNOHISTOCHEMISTRY; KIDNEY DEVELOPMENT; KNOCKOUT MOUSE; LONGEVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN I; ANIMALS; KIDNEY; MICE; MICE, KNOCKOUT; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, SOMATOTROPIN; UP-REGULATION;

EID: 84868512647     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2012.08.003     Document Type: Article

References (57)

1. Vijayakumar A., Novosyadlyy R., Wu Y., Yakar S., LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm. IGF Res. 2010, 20:1-7.
2. Waters M.J., Hoang H.N., Fairlie D.P., Pelekanos R.A., Brown R.J. New insights into growth hormone action. J. Mol. Endocrinol. 2006, 36:1-7.
3. Coschigano K.T., Clemmons D., Bellush L.L., Kopchick J.J. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000, 141:2608-2613.
4. Ikeno Y., Hubbard G.B., Lee S., Cortez L.A., Lew C.M., Webb C.R., Berryman D.E., List E.O., Kopchick J.J., Bartke A. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J. Gerontol. A Biol. Sci. 2009, 64:522-529.
5. Dominici F.P., Arostegui Diaz G., Bartke A., Kopchick J.J., Turyn D. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. J. Endocrinol. 2000, 166:579-590.
6. Bonkowski M.S., Dominici F.P., Arum O., Rocha J.S., Al Regaiey K.A., Westbrook R., Spong A., Panici J., Masternak M.M., Kopchick J.J., Bartke A. Disruption of growth hormone receptor prevents calorie restriction from improving insulin action and longevity. PLoS One 2009, 4:e4567.
7. Liu J.L., Coschigano K.T., Robertson K., Lipsett M., Guo Y., Kopchick J.J., Kumar U., Liu Y.L. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E405-E413.
8. Hauck S.J., Hunter W.S., Danilovich N., Kopchick J.J., Bartke A. Reduced levels of thyroid hormones, insulin, and glucose, and lower body core temperature in the growth hormone receptor/binding protein knockout mouse. Exp. Biol. Med. (Maywood) 2001, 226:552-558.
9. Berryman D.E., List E.O., Coschigano K.T., Behar K., Kim J.K., Kopchick J.J. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm. IGF Res. 2004, 14:309-318.
10. Bartke A., Peluso M.R., Moretz N., Wright C., Bonkowski M., Winters T.A., Shanahan M.F., Kopchick J.J., Banz W.J. Effects of soy-derived diets on plasma and liver lipids, glucose tolerance, and longevity in normal, long-lived and short-lived mice. Horm. Metab. Res. 2004, 36:550-558.
11. Egecioglu E., Bjursell M., Ljungberg A., Dickson S.L., Kopchick J.J., Bergstrom G., Svensson L., Oscarsson J., Tornell J., Bohlooly Y.M. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E317-E325.
12. Egecioglu E., Andersson I.J., Bollano E., Palsdottir V., Gabrielsson B.G., Kopchick J.J., Skott O., Bie P., Isgaard J., Bohlooly Y.M., Bergstrom G., Wickman A. Growth hormone receptor deficiency in mice results in reduced systolic blood pressure and plasma renin, increased aortic eNOS expression, and altered cardiovascular structure and function. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1418-E1425.
13. Roelfsema V., Clark R.G. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. J. Am. Soc. Nephrol. 2001, 12:1297-1306.
14. Izzard A.S., Emerson M., Prehar S., Neyses L., Trainer P., List E.O., Kopchick J.J., Heagerty A.M. The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm. IGF Res. 2009, 19:413-419.
15. Kopchick J.J., Bellush L.L., Coschigano K.T. Transgenic models of growth hormone action. Annu. Rev. Nutr. 1999, 19:437-461.
16. Bellush L.L., Doublier S., Holland A.N., Striker L.J., Striker G.E., Kopchick J.J. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 2000, 141:163-168.
17. Ho K.Y., Weissberger A.J. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism 1990, 39:133-137.
18. Hayes F.J., Fiad T.M., McKenna T.J. Activity of the renin-angiotensin-aldosterone axis is dependent on the occurrence of edema in growth hormone (GH)-deficient adults treated with GH. J. Clin. Endocrinol. Metab. 1997, 82:322-333.
19. Wyse B., Waters M., Sernia C. Stimulation of the renin-angiotensin system by growth hormone in Lewis dwarf rats. Am. J. Physiol. 1993, 265:E332-E339.
20. Wyse B., Sernia C. Growth hormone regulates AT-1a angiotensin receptors in astrocytes. Endocrinology 1997, 138:4176-4180.
21. Mok K.Y., Sandberg K., Sweeny J.M., Zheng W., Lee S., Mulroney S.E. Growth hormone regulation of glomerular AT1 angiotensin receptors in adult uninephrectomized male rats. Am. J. Physiol. Renal Physiol. 2003, 285:F1085-F1091.
22. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006, 86:747-803.
23. Bader M., Ganten D. Update on tissue renin-angiotensin systems. J. Mol. Med. 2008, 86:615-621.
24. Kumar R., Singh V.P., Baker K.M. The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr. Opin. Nephrol. Hypertens. 2008, 17:168-173.
25. Benigni A., Cassis P., Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol. Med. 2010, 2:247-257.
26. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol. Endocrinol. 2006, 20:953-970.
27. Mehta P.K., Griendling K.K. Angiotensin II signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 2007, 292:C82-C87.
28. Shinozaki K., Ayajiki K., Nishio Y., Sugaya T., Kashiwagi A., Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004, 43:255-262.
29. de Cavanagh E.M., Inserra F., Ferder L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?. Cardiovasc. Res. 2011, 89:31-40.
30. Ferrario C.M., Chappell M.C. Novel angiotensin peptides. Cell. Mol. Life Sci. 2004, 61:2720-2727.
31. Santos R.A., Ferreira A.J., Simoes E.S.A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp. Physiol. 2008, 93:519-527.
32. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87:E1-E9.
33. Santos R.A., Simoes e Silva A.C., Maric C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8258-8263.
34. Santos S.H., Fernandes L.R., Mario E.G., Ferreira A.V., Porto L.C., Alvarez-Leite J.I., Botion L.M., Bader M., Alenina N., Santos R.A. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008, 57:340-347.
35. Giani J.F., Mayer M.A., Munoz M.C., Silberman E.A., Hocht C., Taira C.A., Gironacci M.M., Turyn D., Dominici F.P. Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E262-E271.
36. Santos S.H., Braga J.F., Mario E.G., Porto L.C., Rodrigues-Machado Mda G., Murari A., Botion L.M., Alenina N., Bader M., Santos R.A. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler. Thromb. Vasc. Biol. 2010, 30:953-961.
37. Giani J.F., Muñoz M.C., Pons R.A., Cao G., Toblli J.E., Turyn D., Dominici F.P. Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am. J. Physiol. 2011, 300:F272-F282.
38. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
39. List E.O., Sackmann-Sala L., Berryman D.E., Funk K., Kelder B., Gosney E.S., Okada S., Ding J., Cruz-Topete D., Kopchick J.J. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr. Rev. 2011, 32:356-386.
40. Wolf G., Neilson E.G. Angiotensin II as a renal growth factor. J. Am. Soc. Nephrol. 1993, 3:1531-1540.
41. Chen Y., Lasaitiene D., Gabrielsson B.G., Carlsson L.M., Billig H., Carlsson B., Marcussen N., Sun X.F., Friberg P. Neonatal losartan treatment suppresses renal expression of molecules involved in cell-cell and cell-matrix interactions. J. Am. Soc. Nephrol. 2004, 15:1232-1243.
42. Tiwari S., Riazi S., Ecelbarger C.A. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am. J. Physiol. Renal Physiol. 2007, 293:F974-F984.
43. Cooper S.A., Whaley-Connell A., Habibi J., Wei Y., Lastra G., Manrique C., Stas S., Sowers J.R. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2009-H2023.
44. Henriksen E.J. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R974-R980.
45. Ferder L., Inserra F., Romano L., Ercole L., Pszenny V. Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am. J. Physiol. 1993, 265:C15-C18.
46. Bohlooly Y.M., Carlson L., Olsson B., Gustafsson H., Andersson I.J., Tornell J., Bergstrom G. Vascular function and blood pressure in GH transgenic mice. Endocrinology 2001, 142:3317-3323.
47. Chappell M.C. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension 2007, 50:596-599.
48. Giani J.F., Munoz M.C., Mayer M.A., Veiras L.C., Arranz C., Taira C.A., Turyn D., Toblli J.E., Dominici F.P. Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1003-H1013.
49. Benter I.F., Yousif M.H., Dhaunsi G.S., Kaur J., Chappell M.C., Diz D.I. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 2008, 28:25-33.
50. Santos R.A., Castro C.H., Gava E., et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006, 47:996-1002.
51. Crackower M.A., Sarao R., Oudit G.Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-888.
52. Jessup J.A., Gallagher P.E., Averill D.B., Brosnihan K.B., Tallant E.A., Chappell M.C., Ferrario C.M. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2166-H2172.
53. Gallagher P.E., Chappell M.C., Ferrario C.M., Tallant E.A. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am. J. Physiol. Cell Physiol. 2006, 290:C420-C426.
54. Zhong J., Basu R., Guo D., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010, 122:717-728.
55. Oudit G.Y., Herzenberg A.M., Kassiri Z., Wong D., Reich H., Khokha R., Crackower M.A., Backx P.H., Penninger J.M., Scholey J.W. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am. J. Pathol. 2006, 168:1808-1820.
56. Zhong J., Guo D., Chen C.B., Wang W., Schuster M., Loibner H., Penninger J.M., Scholey J.W., Kassiri Z., Oudit G.Y. Prevention of angiotensin ii-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 2011, 57:314-322.
57. Gwathmey T.M., Westwood B.M., Pirro N.T., Tang L., Rose J.C., Diz D.I., Chappell M.C. Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide. Am. J. Physiol. Renal Physiol. 2010, 299:F983-F989.